BioNexus Gene Lab (BGLC) Depreciation & Amortization (CF) (2018 - 2026)

BioNexus Gene Lab has disclosed Depreciation & Amortization (CF) across 9 years of filings, most recently posting $28293.0 for Q1 2026.

• Depreciation & Amortization (CF) for Q1 2026 came in at $28293.0, up 6.2% year-over-year; the trailing twelve-month figure through Mar 2026 was $113524.0 (up 2.58% YoY), and the FY2025 annual result was $111873.0, up 7.4% from the prior year.
• Depreciation & Amortization (CF) came in at $28293.0 for Q1 2026 at BioNexus Gene Lab, roughly flat from $28430.0 in the prior quarter.
• In the past five years, Depreciation & Amortization (CF) ranged from a high of $63129.0 in Q3 2023 to a low of -$20879.0 in Q2 2023.
• The 5-year median for Depreciation & Amortization (CF) is $24819.0 (2022), against an average of $24647.4.
• Across the five-year window, Depreciation & Amortization (CF) plunged 192.24% in 2023 and jumped 196.77% in 2024, its largest moves.
• BioNexus Gene Lab's Depreciation & Amortization (CF) stood at $24819.0 in 2022, then dropped by 18.99% to $20106.0 in 2023, then jumped by 46.97% to $29549.0 in 2024, then decreased by 3.79% to $28430.0 in 2025, then fell by 0.48% to $28293.0 in 2026.
• The last three Depreciation & Amortization (CF) figures came in at $28293.0 (Q1 2026), $28430.0 (Q4 2025), and $29001.0 (Q3 2025), per Business Quant data.